Abstract 50P
Background
In 2020 we initiated a 10-year precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing (RNAseq) at Aalborg University Hospital, Denmark - a midsize, regional public academic hospital. Here we present updated results of the clinical impact in the first three years.
Methods
We included 236 eligible, adult patients with late-stage cancer of any diagnosis from June 2020 to May 2023 in the Proseq Cancer trial. Molecular profiling of new or fresh frozen tumor biopsies was done by WES and RNAseq with parallel sequencing of non-tumoral DNA as individual reference. Cases were presented at the National Molecular Tumor Board (NMTB) for discussion of targeted treatment. Treatment was available through a multicenter basket trial (Protarget, NCT04341181), phase I-trials, or by compassionate/off label use.
Results
A targeted treatment was suggested for 72 patients (31%) at the NMTB. Of these, 23 patients initiated treatment and 11 patients are still waiting for treatment. Reasons for no treatment were: patients general condition worsened (22 patients), no available drug (6 patients), patient declined (6 patients), and prior treatment against same target (4 patients). A total of 27 treatments were initiated, most commonly targeted against ERBB2, TMB-high, MSI, BRCA/ATM and BRAF-V600E. The response rate was 44% (among 18 evaluable), and the clinical benefit rate was 52% (among 23 evaluable). Median treatment duration was 3 months (range, 2 weeks to +2 years). The median overall survival from the date of NMTB was 6, 6 and 15 months, respectively, for patients with no recommendation of targeted treatment, with recommended targeted treatment not initiated, and with recommended targeted treatment initiated (P=0.01).
Conclusions
Precision medicine in end-stage cancer patients is feasible in a regional academic hospital through close collaboration with comprehensive cancer centers and nationwide access to drug trials. Although efficacy of targeted treatments is encouraging, the overall clinical impact in this poor prognosis population is modest.
Editorial acknowledgement
Clinical trial identification
NCT05695638; January 25, 2023.
Legal entity responsible for the study
M. Ladekarl.
Funding
The Council of the North Denmark Region and H.E. & N.C. Brogaards Legat til Kræftforskningens Fremme.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract